围术期嗅球刺激对于老年患者术后谵妄的作用:一项单中心、随机对照临床研究

注册号:

Registration number:

ChiCTR2500113236 

最近更新日期:

Date of Last Refreshed on:

2025-11-26 11:08:40 

注册时间:

Date of Registration:

2025-11-26 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

围术期嗅球刺激对于老年患者术后谵妄的作用:一项单中心、随机对照临床研究

Public title:

The Effect of Perioperative Olfactory Bulb Stimulation on Postoperative Delirium in Elderly Patients: A Single-Center, Randomized Controlled Clinical Trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

围术期嗅球刺激对于老年患者术后谵妄的作用:一项单中心、随机对照临床研究

Scientific title:

The Effect of Perioperative Olfactory Bulb Stimulation on Postoperative Delirium in Elderly Patients: A Single-Center, Randomized Controlled Clinical Trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘阳 

研究负责人:

谭宏宇 

Applicant:

Liu Yang 

Study leader:

Tan Hongyu 

申请注册联系人电话:

Applicant telephone:

+86 153 3023 2249

研究负责人电话:

Study leader's
telephone:

+86 10 8819 6553

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1412691463@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1412691463@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国北京市海淀区阜成路52号

研究负责人通讯地址:

中国北京市海淀区阜成路52号

Applicant address:

52 Fucheng Road, Haidian District, Beijing, China

Study leader's address:

52 Fucheng Road, Haidian District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京大学肿瘤医院

Applicant's institution:

Peking University Cancer Hospital

研究负责人所在单位:

北京大学肿瘤医院

Affiliation of the Leader:

Peking University Cancer Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025YJZ124

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京肿瘤医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Beijing Cancer Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-10-24 00:00:00

伦理委员会联系人:

张老师

Contact Name of the ethic committee:

Teacher Zhang

伦理委员会联系地址:

中国北京市海淀区阜成路52号

Contact Address of the ethic committee:

52 Fucheng Road, Haidian District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8819 6913

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学肿瘤医院

Primary sponsor:

Peking University Cancer Hospital

研究实施负责(组长)单位地址:

中国北京市海淀区阜成路52号

Primary sponsor's address:

52 Fucheng Road, Haidian District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学肿瘤医院

具体地址:

中国北京市海淀区阜成路52号

Institution
hospital:

Peking University Cancer Hospital

Address:

52 Fucheng Road, Haidian District, Beijing, China

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

研究疾病:

术后谵妄  

Target disease:

Postoperative delirium

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.主要研究目的为围术期嗅球刺激对于POD的改善作用,包括发生率、严重程度和持续时间。 2.次要研究目的为围术期嗅球刺激对围术期并发症的影响。  

Objectives of Study:

1.The primary objective of the study is to evaluate the efficacy of perioperative olfactory bulb stimulation in improving postoperative delirium (POD), including its incidence, severity, and duration. 2.The secondary objective is to assess the impact of perioperative olfactory bulb stimulation on perioperative complications.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.既往存在术后谵妄、认知功能障碍及老年痴呆病史的患者;2.既往行鼻腔手术的患者;3.术前存在严重神经系统疾病(如脑卒中、帕金森病);4.非插管全麻的患者;5.无法配合完成试验的患者。

Exclusion criteria:

1.Patients with a history of postoperative delirium, cognitive impairment, or dementia; 2.Patients with a history of prior nasal surgery; 3.Patients with severe preoperative neurological disorders (e.g., stroke, Parkinson’s disease); 4.Patients undergoing non-intubated general anesthesia; 5.Patients unable to comply with or complete the study procedures.

研究实施时间:

Study execute time:

From 2025-12-01 00:00:00 To 2026-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-12-01 00:00:00 To 2026-12-01 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

183

Group:

Intervention group

Sample size:

干预措施:

干预组在术中接受嗅球刺激(即鼻导管吸氧),氧流量3L/min,湿化器内添加5ml薰衣草精油。

干预措施代码:

Intervention:

The intervention group received olfactory bulb stimulation during surgery (administered via nasal cannula oxygen therapy) at an oxygen flow rate of 3 L/min, with 5 mL of lavender essential oil added to the humidifier.

Intervention code:

组别:

对照组

样本量:

183

Group:

Control group

Sample size:

干预措施:

对照组术中不进行鼻导管吸氧

干预措施代码:

Intervention:

The control group did not receive nasal cannula oxygen therapy during surgery.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学肿瘤医院 

单位级别:

三甲 

Institution
hospital:

Peking University Cancer hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后谵妄

指标类型:

主要指标

Outcome:

Postoperative delirium

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

认知功能

指标类型:

次要指标

Outcome:

Cognitive function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑抑郁评分(HADS)

指标类型:

次要指标

Outcome:

Anxiety-Depression score (HADS)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛评分

指标类型:

次要指标

Outcome:

Pain score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后并发症

指标类型:

次要指标

Outcome:

Postoperative complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机化采用区块随机化的方法,使用随机数表生成不重复的随机序列,将参与对象随机分配到干预组或对照组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomization was performed using block randomization. A non-repeating random sequence was generated using a random number table to allocate participants randomly to either the intervention group or the control group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

本研究的盲法采用双盲,参与对象在围术期对接受的干预方法不知情,研究人员在随访及数据分析过程中对研究对象分组不知情。

Blinding:

This study employed a double-blind design: participants were unaware of the intervention they received during the perioperative period, and the researchers conducting follow-up assessments and data analysis were blinded to the group assignments of the participants.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

对原始CRF核实无误后,用电子数据采集系统(EDC)建立数据库,由两名经过培训的数据录入员独立进行数据录入,之后进行双录入核查。数据库不一致时,逐项核对原始记录表进行校对,完成后锁定数据库。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

After verification of the original Case Report Forms (CRFs) for accuracy, a database was established using an Electronic Data Capture (EDC) system. Two trained data entry personnel independently performed data entry, followed by dual-entry verification. In the event of discrepancies in the database, each item was cross-checked against the original CRFs for correction. Upon completion of this process, the database was locked.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-11-26 11:08:40